Luoxin Pharmaceutical released its 2026 interim report on August 21, 2026. Total operating revenue was 1.147 billion yuan, net profit attributable to the parent company was 49.93 million yuan, and net cash inflow from operating activities was 310 million yuan. The latest asset-liability ratio was 66.72 percent, up 4.79 percentage points from the same period last year. The latest gross margin was 60.53 percent, down 0.48 percentage points from the previous quarter. The latest return on equity was 4.43 percent, and diluted earnings per share was 0.05 yuan. The latest total asset turnover was 0.31 times, and the latest inventory turnover was 1.31 times. The number of shareholders was 35,000, and the top ten shareholders held 555 million shares, accounting for 51.03 percent of total share capital.
Luoxin Pharmaceuticals Group Stock Co LtdCompany released interim report with net profit of 49.93 million yuan, indicating profitability.
